type 1 diabetes

Vertex Presents Positive, Updated VX-880 Results From Ongoing Phase 1/2 Study in Type 1 Diabetes at the European Association for the Study of Diabetes 59th Annual Meeting
Vertex Presents Positive, Updated VX-880 Results From Ongoing Phase 1/2 Study in Type 1 Diabetes at the European Association for the Study of Diabetes 59th Annual Meeting
Businesswire
Vertex Pharmaceuticals
VX-880
clinical trials
type 1 diabetes
Flag link:
After treatment with semaglutide, people with newly diagnosed type 1 diabetes needed little or no insulin
After treatment with semaglutide, people with newly diagnosed type 1 diabetes needed little or no insulin
Medical News Today
Novo Nordisk
Ozempic
semaglutide
type 1 diabetes
Flag link:
After First Approval, Experts Point to Barriers in Cell Therapy for Type 1 Diabetes
After First Approval, Experts Point to Barriers in Cell Therapy for Type 1 Diabetes
BioSpace
CellTrans
Lantidra
type 1 diabetes
cell therapy
Eli Lilly
Siglion Therapeutics
Flag link:
FDA blesses CellTrans' Lantidra, the first cell therapy for Type 1 diabetes
FDA blesses CellTrans' Lantidra, the first cell therapy for Type 1 diabetes
Fierce Pharma
CellTrans
Lantidra
donislecel
cell therapy
type 1 diabetes
Flag link:
Sernova reports positive interim data for Cell Pouch System
Sernova reports positive interim data for Cell Pouch System
Drug Delivery Business
Sernova
Cell Pouch System
type 1 diabetes
Medtech
Flag link:
AstraZeneca Teams Up With Startup Quell in Type 1 Diabetes, IBD Cell Therapy Pact
AstraZeneca Teams Up With Startup Quell in Type 1 Diabetes, IBD Cell Therapy Pact
MedCity News
AstraZeneca
Quell Therapeutics
type 1 diabetes
IBD
cell therapy
Flag link:
DiogenX SA raises €27.5M in Series A financing for type 1 diabetes work
DiogenX SA raises €27.5M in Series A financing for type 1 diabetes work
European Biotechnology
DiogenX
funding
type 1 diabetes
Flag link:
Sigilon focuses on type 1 diabetes, reduces spend on MPS-1 after letting CMO go
Sigilon focuses on type 1 diabetes, reduces spend on MPS-1 after letting CMO go
Endpoints
Siglion Therapeutics
type 1 diabetes
cell therapy
Flag link:
Canadian royalty investor buys into first-of-its-kind Type 1 diabetes drug
Canadian royalty investor buys into first-of-its-kind Type 1 diabetes drug
BioPharma Dive
DRI Healthcare Trust
type 1 diabetes
Macrogenics
Tzield
Flag link:
Vertex's next off-the-shelf diabetes cell therapy follows in predecessor's footsteps to the clinic
Vertex's next off-the-shelf diabetes cell therapy follows in predecessor's footsteps to the clinic
Fierce Biotech
Vertex Pharmaceuticals
type 1 diabetes
cell therapy
VX-264
Flag link:
Medtronic links MiniMed 780G automated insulin delivery to sustained glucose control benefits
Medtronic links MiniMed 780G automated insulin delivery to sustained glucose control benefits
Medtech Dive
Medtronic
devices
Medtech
diabetes
MiniMed 780G
type 1 diabetes
Flag link:
Delaying type 1 diabetes progression: major trial readouts to watch in 2023
Delaying type 1 diabetes progression: major trial readouts to watch in 2023
Clinical Trials Arena
clinical trials
type 1 diabetes
Provention Bio
Tzeild
Diamyd Medical
remygen
Imcyse
IMCY-0098
ProKidney
Flag link:
Panbela begins Phase II trial of type 1 diabetes therapy trial
Panbela begins Phase II trial of type 1 diabetes therapy trial
Clinical Trials Arena
Panbela Therapeutics
clinical trials
CPP-1X-T
type 1 diabetes
Flag link:
Diamyd Diabetes Vaccine Study gets Green Light to Resume by the FDA
Diamyd Diabetes Vaccine Study gets Green Light to Resume by the FDA
Xtalks
Diamyd Medical
type 1 diabetes
FDA
clinical trials
Diamyd
Flag link:
Lexicon slams FDA over hearing denial following a CRL for its SGLT2 inhibitor candidate
Lexicon slams FDA over hearing denial following a CRL for its SGLT2 inhibitor candidate
Endpoints
Lexicon Pharmaceuticals
FDA
type 1 diabetes
sotagliflozin
Flag link:
FDA lifts partial clinical suspension on Diamyd’s diabetes therapy trial
FDA lifts partial clinical suspension on Diamyd’s diabetes therapy trial
Clinical Trials Arena
Diamyd Medical
clinical trials
FDA
type 1 diabetes
Diamyd
Flag link:
FDA greenlights Provention Bio's diabetes drug
FDA greenlights Provention Bio's diabetes drug
Yahoo/Reuters
Provention Bio
type 1 diabetes
FDA
teplizumab
Flag link:
The global diabetes crisis few are talking about
The global diabetes crisis few are talking about
Stat
diabetes
type 1 diabetes
patient access
Flag link:
Anticipating FDA Yes, Provention Inks Co-Promotion Deal with Sanofi for T1D Drug
Anticipating FDA Yes, Provention Inks Co-Promotion Deal with Sanofi for T1D Drug
BioSpace
Provention Bio
Sanofi
type 1 diabetes
teplizumab
Flag link:
New model says Type 1 diabetes cases worldwide could double by 2040
New model says Type 1 diabetes cases worldwide could double by 2040
Washington Post, DC
type 1 diabetes
Flag link:

Pages